NVAX
Price
$6.88
Change
-$0.09 (-1.29%)
Updated
Jul 15 closing price
Capitalization
1.11B
21 days until earnings call
PRTA
Price
$6.22
Change
-$0.21 (-3.27%)
Updated
Jul 15 closing price
Capitalization
334.8M
22 days until earnings call
REPL
Price
$12.40
Change
+$1.12 (+9.93%)
Updated
Jul 15 closing price
Capitalization
955.88M
15 days until earnings call
Interact to see
Advertisement

NVAX or PRTA or REPL

Header iconNVAX vs PRTA vs REPL Comparison
Open Charts NVAX vs PRTA vs REPLBanner chart's image
Novavax
Price$6.88
Change-$0.09 (-1.29%)
Volume$3.79M
Capitalization1.11B
Prothena
Price$6.22
Change-$0.21 (-3.27%)
Volume$730.5K
Capitalization334.8M
Replimune Group
Price$12.40
Change+$1.12 (+9.93%)
Volume$4.9M
Capitalization955.88M
NVAX vs PRTA vs REPL Comparison Chart in %
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
Interact to see
Advertisement
COMPARISON
Comparison
Jul 16, 2025
Stock price -- (NVAX: $6.88PRTA: $6.22REPL: $12.40)
Brand notoriety: PRTA and REPL are not notable and NVAX is notable
The three companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 46%, PRTA: 42%, REPL: 340%
Market capitalization -- NVAX: $1.11B, PRTA: $334.8M, REPL: $955.88M
$NVAX is valued at $1.11B, while PRTA has a market capitalization of $334.8M, and REPL's market capitalization is $955.88M. The market cap for tickers in this @Biotechnology ranges from $308.32B to $0. The average market capitalization across the @Biotechnology industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s), and REPL’s FA Score reflects 0 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • PRTA’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 0 green, 5 red.
According to our system of comparison, REPL is a better buy in the long-term than NVAX and PRTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while PRTA’s TA Score has 6 bullish TA indicator(s), and REPL’s TA Score reflects 4 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 4 bearish.
  • PRTA’s TA Score: 6 bullish, 3 bearish.
  • REPL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PRTA is a better buy in the short-term than NVAX, which in turn is a better option than REPL.

Price Growth

NVAX (@Biotechnology) experienced а -2.27% price change this week, while PRTA (@Biotechnology) price change was -4.60% , and REPL (@Biotechnology) price fluctuated +32.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.

Reported Earning Dates

NVAX is expected to report earnings on Nov 05, 2025.

PRTA is expected to report earnings on Oct 30, 2025.

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+2.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.11B) has a higher market cap than REPL($956M) and PRTA($335M). REPL YTD gains are higher at: 2.395 vs. NVAX (-14.428) and PRTA (-55.090). NVAX has higher annual earnings (EBITDA): 555M vs. PRTA (-137.71M) and REPL (-235.43M). NVAX has more cash in the bank: 731M vs. REPL (484M) and PRTA (418M). PRTA has less debt than REPL and NVAX: PRTA (10.2M) vs REPL (76.2M) and NVAX (229M). NVAX has higher revenues than PRTA and REPL: NVAX (1.22B) vs PRTA (138M) and REPL (0).
NVAXPRTAREPL
Capitalization1.11B335M956M
EBITDA555M-137.71M-235.43M
Gain YTD-14.428-55.0902.395
P/E Ratio2.50N/AN/A
Revenue1.22B138M0
Total Cash731M418M484M
Total Debt229M10.2M76.2M
FUNDAMENTALS RATINGS
NVAX vs PRTA vs REPL: Fundamental Ratings
NVAX
PRTA
REPL
OUTLOOK RATING
1..100
152126
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100100
SMR RATING
1..100
100100100
PRICE GROWTH RATING
1..100
636541
P/E GROWTH RATING
1..100
100100100
SEASONALITY SCORE
1..100
n/an/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVAX's Valuation (50) in the Biotechnology industry is in the same range as PRTA (50) and is in the same range as REPL (50). This means that NVAX's stock grew similarly to PRTA’s and similarly to REPL’s over the last 12 months.

NVAX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRTA (100) and is in the same range as REPL (100). This means that NVAX's stock grew similarly to PRTA’s and similarly to REPL’s over the last 12 months.

NVAX's SMR Rating (100) in the Biotechnology industry is in the same range as PRTA (100) and is in the same range as REPL (100). This means that NVAX's stock grew similarly to PRTA’s and similarly to REPL’s over the last 12 months.

REPL's Price Growth Rating (41) in the Biotechnology industry is in the same range as NVAX (63) and is in the same range as PRTA (65). This means that REPL's stock grew similarly to NVAX’s and similarly to PRTA’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NVAX (100) and is in the same range as PRTA (100). This means that REPL's stock grew similarly to NVAX’s and similarly to PRTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXPRTAREPL
RSI
ODDS (%)
N/A
Bullish Trend 6 days ago
80%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 7 days ago
74%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 16 days ago
89%
Bearish Trend 5 days ago
87%
Bearish Trend 15 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LDNXF145.600.10
+0.07%
London Stock Exchange Ltd.
CSNVY21.58N/A
N/A
Corbion NV
DIPGF0.26N/A
N/A
Datang International Power Generation Co., Ltd.
OPORF0.24N/A
N/A
OPEN ORPHAN PLC.
GTHP0.25-0.01
-3.85%
Guided Therapeutics, Inc.

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with RCKT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
-3.27%
RCKT - PRTA
53%
Loosely correlated
-7.87%
SVRA - PRTA
46%
Loosely correlated
-8.76%
DNLI - PRTA
42%
Loosely correlated
-3.54%
KRYS - PRTA
39%
Loosely correlated
-1.78%
AXON - PRTA
38%
Loosely correlated
-0.59%
More